Distal Myopathy with Rimmed Vacuoles

Impaired O-Glycan Formation in Muscular Glycoproteins

Youichi Tajima,* Eiichiro Uyama,† Shinji Go,** Chihiro Sato,** Nodoka Tao,* Masaharu Kotani,* Hirotake Hino,* Akemi Suzuki,** Yutaka Sanai,** Ken Kitajima,** and Hitoshi Sakuraba*
From the Departments of Clinical Genetics* and Biochemical Cell Research,** The Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Organization for Medical Research, Tokyo; the Department of Neurology Advanced Biomedical Sciences,‡ Faculty of Medical and Pharmaceutical Sciences, Graduate School of Medical Sciences, Kumamoto University, Kumamoto; the Division of Organogenesis,§ Bioscience, and Biotechnology Center, Nagoya University, Nagoya; and Supra-Biomolecular Research System,** Riken Frontier Research System, Riken, Wako, Japan

Distal myopathy with rimmed vacuoles (DMRV), is an autosomal recessive disorder with early adult onset, displays distal dominant muscular involvement and is characterized by the presence of numerous rimmed vacuoles in the affected muscle fibers. The pathophysiology of DMRV has not been clarified yet, although the responsible gene was identified as that encoding UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase involved in the biosynthesis of sialic acids. To identify defective carbohydrate moieties of muscular glycoproteins from DMRV patients, frozen skeletal muscle sections from seven patients with DMRV, as well as normal and pathological controls, were treated with or without sialidase or N-glycosidase F followed by lectin staining and lectin blotting analysis. The sialic acid contents of the O-glycans in the skeletal muscle specimens from the DMRV patients were also measured. We found that Arachis hypogaea agglutinin (PNA) lectin reacted strongly with sarcolemmal glycoproteins in the DMRV patients but not with those in control subjects. α-Dystroglycan from the DMRV patients strongly associated with PNA lectin, although that from controls did not. The sialic acid level of the O-glycans in the DMRV muscular glycoproteins with molecular weights of 30 to 200 kd was reduced to 60 to 80% of the control level. The results show that impaired sialyl O-glycan formation in muscular glycoproteins, including α-dystroglycan, occurs in DMRV. (Am J Pathol 2005, 166:1121–1130)

Distal myopathy with rimmed vacuoles (DMRV), also known as Nonaka distal myopathy (OMIM 605820), is an autosomal recessive muscular disease that was delineated in Japan. The disease is characterized by early-adult onset with weakness of the tibialis anterior muscles, sparing of the quadriceps muscles until the late stage, and the presence of numerous rimmed vacuoles in affected muscle fibers without infiltration by inflammatory cells.¹ Previous linkage studies²,³ indicated that DMRV is allelic to hereditary inclusion body myopathy (HIBM), also known as IBM2 (OMIM 600737), a similar autosomal recessive disorder that was delineated among Jews originating from Middle Eastern countries.³,⁵,⁶ This disease is the most common form of ethnic-related familial degenerative myopathy in Israel, with a prevalence of 1:1500 in the Jewish-Persian community.⁷ Recently, Eisenberg and colleagues⁸ identified mutations in the UDP-N-acetylgalactosamine 2-epimerase/N-acetylmannosamine kinase (UDP-GlcNAc 2-epimerase) (EC 5.1.3.14/2.7.1.60) gene (GNE) in HIBM families. Then, mutations were identified in the same gene in Japanese patients with DMRV, as expected.⁹–¹²

UDP-GlcNAc 2-epimerase has been shown to be the key enzyme in the sialic acid biosynthetic pathway.¹³ This enzyme is bifunctional, having epimerase activity, in the amino-terminal region, and kinase activity, in the carboxy-terminal region,¹⁴ and is involved in the first two steps of the biosynthesis of N-acetylneuraminic acid

Supported by grants from the Ministry of Education, Science, Sports, and Culture of Japan (to H.S.); the Ministry of Health, Labor, and Welfare of Japan (to H.S.); the Japan Society for the Promotion of Science (to H. S. and grants-in-aid for scientific research (C) (to Y.T., M.K., and E.U.); the Tokyo Metropolitan Government (to H.S. and Y.S.); and the Ichiro Kanehara Foundation (to Y.T.).

Accepted for publication December 20, 2004.

Address reprint requests to Dr. Hitoshi Sakuraba, Department of Clinical Genetics, The Tokyo Metropolitan Institute of Medical Science, Tokyo Metropolitan Organization for Medical Research, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan. E-mail: sakuraba@rinshoken.or.jp.
(NeuAc).\textsuperscript{15} NeuAc is a common sialic acid in humans and the precursor of sialic acid compounds. Sialic acids are carbohydrates found on the cell surface, where they mediate a lot of cellular functions, e.g., cell-cell or cell-matrix interactions. As the modification of sialic acid-containing glycoproteins and glycolipids on the cell surface is essential for biological functions, a genetic defect in the enzyme might cause a myopathy such as DMRV/HIBM. Mutations associated with DMRV/HIBM have been identified in both the epimerase and kinase domains.\textsuperscript{8} Recent studies revealed that GNE mutations including a common one for Japanese DMRV patients, V572L, cause reduction of UDP-GlcNAc 2-epimerase/ManNAc kinase activity.\textsuperscript{16} This enzyme is known to be a key enzyme in the sialic acid biosynthetic pathway. However, what the enzyme defect causes is obscure.

In this study, we examined the carbohydrate moieties of muscular glycoproteins from DMRV and control cases, using lectins and glycosidases to elucidate what a genetic defect in GNE results in.

\textbf{Materials and Methods}

\textbf{Patients}

Seven affected individuals from five unrelated Japanese families with DMRV [DMRV-1: a 34-year-old male; DMRV-2: a 31-year-old male; DMRV-3: a 53-year-old female; DMRV-4: an 18-year-old female; and DMRV-5 brother (B): a 31-year-old male; DMRV-5 sister-1 (S-1): a 30-year-old female; and DMRV-5 sister-2 (S-2): a 29-year old female; the latter three being siblings from the same family], a patient with facioscapulo humeral muscular dystrophy (FSHD, a 59-year-old male), a patient with oculopharyngeal muscular dystrophy (OPMD, a 50-year-old female), a patient with Emery-Dreifuss muscular dystrophy (EDMD, a 41-year-old male), a patient with myotonic dystrophy (MD, a 45-year-old male), and four normal controls (N1 and N2), pathological controls (OPMD, EDMD, and MD), and the DMRV patients (DMRV-1 to DMRV-5S-2). In brief, frozen sections (8\textmu m) were mounted on glass slides, dried at room temperature for 1 hour, fixed in cold acetone or 4\% paraformaldehyde in phosphate-buffered saline (PBS) for 1 minute at room temperature, and then incubated with 1\% bovine serum albumin-PBS. The sections were then incubated with the above primary antibodies overnight at 4°C, followed by incubation with fluorescein isothiocyanate-isothiocyanate-labeled (200-fold diluted), Cy3-labeled (300-fold diluted) (Jackson ImmunoResearch, West Grove, PA), Alexa Fluor 488-labeled (1000-fold), or Alexa Fluor 594-labeled (1000-fold) secondary antibodies (Molecular Probes, Eugene, OR) as described previously.\textsuperscript{23}

For lectin staining, frozen skeletal muscle tissue sections from the patients with DMRV and the normal controls were incubated with the following fluorescent isothiocyanate-labeled or rhodamine isothiocyanate-labeled lectins: \textit{Wheat germ} agglutinin (WGA, 1 \mu g/ml), \textit{Arachis hypogaea} (peanut) agglutinin (PNA, 1 \mu g/ml), \textit{Glycine max} (soybean) agglutinin (SBA, 1 \mu g/ml), \textit{Datura stramonium} agglutinin (DSA, 1 \mu g/ml), \textit{Ricinus communis} agglutinin (RCA, 1 \mu g/ml) (Vector Laboratories Inc., Burlingame, CA), and \textit{Maackia amurensis} agglutinin (MAA, 1 \mu g/ml) (EY Laboratories, San Mateo, CA) in 1\% bovine serum albumin-PBS for 1 hour at room temperature.\textsuperscript{26} The stained sections were observed under a microscope (Axiovert 1000M; Carl Zeiss, Oberkochen, Germany) equipped with a laser-scanning confocal imaging system, LSM510 (Carl Zeiss). Digitized images were captured under identical conditions.
Western Blotting and Lectin Blotting

Frozen skeletal muscle sections from the DMRV patients and controls including normal subjects were sonicated in 100 μl of Triton X lysis buffer (1% Triton X, 150 mmol/L NaCl, and 20 mmol/L Tris-HCl, pH 7.5). The tissue extracts were centrifuged at 10,000 × g for 5 minutes at 4°C to remove the insoluble debris. Then, the supernatants were treated with trichloroacetic acid, followed by centrifugation at 10,000 × g for 5 minutes at 4°C. The trichloroacetic acid pellets were resuspended in 20 μl of Triton X lysis buffer, and then neutralized with 1 mol/L Tris-HCl (pH 9.0). Sample protein concentration was performed using micro BCA protein assay reagent (Pierce, Rockford, IL). Twenty μg aliquots of protein of the tissue extracts were solubilized with an equal volume of sodium dodecyl sulfate (SDS) sample buffer (62.5 mmol/L Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, and 5% β-mercaptoethanol). Then, they were separated on a 4 to 20% Tris-glycine polyacrylamide gel (PAGE mini; Daiichi Pure Chemical Co., Ltd., Tokyo, Japan), and then electrotransferred to polyvinylidene difluoride (PVDF) Immobilon-P membranes (Millipore Corp., Bedford, MA). For Western blotting, the blots were blocked in Tris-buffered saline (20 mmol/L Tris-HCl, pH 7.5, 100 mmol/L NaCl) containing 5% skim milk for 15 minutes at room temperature. Then, they were probed with an anti-α-DG antibody (clone IIH6) at a dilution of 1:500 in Tris-buffered saline containing 5% skim milk for 1 hour at room temperature. After the blots had been washed with Tris-buffered saline three times, then probed with a peroxidase-conjugated donkey anti-mouse secondary antibody (Amersham Pharmacia Biotech, Arlington Heights, IL) for 1 hour at room temperature. Then, the blots were washed with Tris-buffered saline three times, and then developed with ECL (Amer- sham Pharmacia Biotech) as the chemiluminescent substrate on Hyperfilm ECL (Amer- sham Pharmacia Biotech) for varying times (1 to 10 minutes).

Specific binding of lectins was used for identification of the carbohydrate moieties in extracts of the frozen skeletal muscle tissues, according to the manufacturer’s specifications (DIG glycan differentiation kit; Roche Molecular Biochemicals). PVDF membranes with the extracts that had been separated by SDS-polyacrylamide gel electrophoresis (PAGE) were incubated for 1 hour with PNA and MAA lectins conjugated to the steroid hapten digoxigenin (DIG). After washing the membranes, glycoproteins were detected with anti-DIG Fab fragments conjugated with alkaline phosphatase, followed by detection with CDP-star (Roche Molecular Biochemicals) as the chemiluminescent substrate.

Chemical Analysis of Oligosaccharide Chains on Glycoproteins Blotted on PVDF Membranes

The sialic acid content was determined by fluorometric analysis using the α-keto acid-specific reagent 1,2-diamo-3,4-methylenedioxybenzene (DMB). Skeletal muscle glycoproteins from the DMRV patients and controls including normal controls blotted onto PVDF membranes were analyzed by the mild acid hydrolysis-fluorometric HPLC method, as described previously.

Enzyme Treatments

Sections were treated with 50 mU sialidase from Clostridium perfringens (Roche, Mannheim, Germany) in 50 mmol/L sodium acetate (pH 5.0) for 6 hours at 37°C or with 5 U N-glycosidase F (Roche) in PBS for 12 hours at 37°C, respectively. Then, samples were analyzed by means of lectin staining and lectin blotting.

Lectin Precipitation

Frozen skeletal muscle sections were solubilized in 100 μl of Triton X lysis buffer. The extracted proteins were added to 20 μl of PNA-agarose (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) overnight with shaking at 4°C. The precipitated proteins were washed extensively in Triton X lysis buffer and then boiled in SDS sample buffer. The supernatant (not binding PNA-agarose) was treated with trichloroacetic acid, followed by centrifugation at 10,000 × g for 5 minutes at 4°C, and then solubilization in SDS sample buffer. The proteins were separated and blotted as described above, and then detected with anti-α-DG antibody IIH6.

Statistical Analysis

The data in this study were presented as means ± SD. Statistical comparisons were conducted by means of Student’s t-test under the conditions of two-tailed distribution and two-sample equal variance.

Results

To identify carbohydrate moieties in muscular glycoproteins of both the DMRV patients and control subjects, lectin-staining of frozen sections from normal controls (N1 and N2), pathological controls (OPMD, EDMD, and MD), and the DMRV patients (DMRV-1 to DMRV-5S-2) was analyzed. We used five lectins in this study, ie, PNA (specific for Galβ1-3GalNAc), SBA (specific for GalNAca1-3Gal), RCA120 (specific for GalNAc and Neu5Aç), and MAA (specific for Neu5Aç2-3Gal). PNA lectin reacted strongly with the sarcolemma and connective tissues in skeletal muscle sections from all seven DMRV patients (Figure 1), whereas it hardly stained those in normal controls and the OPMD patient under the described conditions (Figure 1A). Furthermore, we double-stained skeletal muscle sections with PNA lectin and an antibody against dystrophin, a classical sarcolemma marker, to determine the localization of PNA reactivity in the DMRV muscles. The merged images clearly show that there is co-localization of PNA-reactive materials and dystrophin in the DMRV muscle, although weak PNA reactivity is also present in the connective tissues (Figure 1B). In contrast, PNA stained the connective tissues of the MD, EDMD, and
normal control muscles (Figure 1B). These results indicate an increase in the disaccharide Galβ1-3GalNAc unit in the plasma membranes of the DMRV skeletal muscles.

SBA lectin stained the connective tissues in the DMRV muscles stronger than those in a control (Figure 2A). Rimmed vacuoles, which were confirmed by means of phase contrast microscopy, showed increased reactivity with SBA (Figure 2A). The sarcoplasm of several atrophic fibers in DMRV sections also showed increased reactivity with SBA (Figure 2A). The SBA reactivity was stronger in the rimmed vacuoles and sarcoplasm of the atrophic fibers in DMRV than in connective tissues. We next double stained the DMRV muscles with SBA lectin and an antibody against dystrophin. The localization of SBA-reactive materials was apparently different from that of dystrophin (Figure 2B). This suggested that the SBA-reactive materials are not localized in the sarcolemma. RCA120 lectin reacted with the sarcolemma, connective tissues, and blood vessels in the DMRV skeletal muscles, although it also reacted with those in controls. The rimmed vacuoles and sarcoplasm of the atrophic fibers in DMRV were stained strongly (Figure 2A). These results indicate that terminal Gal and GalNAcβ1-3Gal carbohydrate moieties are increased in the rimmed vacuoles and sarcoplasm of atrophic fibers in DMRV. In contrast, MAA and WGA stained the sarcolemma, connective tissues, and blood vessels in both the control and DMRV patient muscles (Figure 2). These results indicate the presence of Neu5Acβ2-3Gal and (GlcNAc)n carbohydrate moieties in both the DMRV and control skeletal muscles.

To confirm the results of lectin staining, we performed lectin blotting analysis with a highly specific DIG-labeled lectin-CDP-star ECL system. MAA reacted strongly with a major band at 250 kd and several minor bands for both control and DMRV muscle cell extracts (Figure 3A). In contrast, PNA reacted with highly glycosylated broad bands at ~200 kd for cell extracts of the DMRV skeletal muscle specimens, but not in control specimens (Figure 3B).

The increase in PNA reactivity to DMRV skeletal muscle glycoproteins could be because of an increase in Galβ1-3GalNAc moieties. Alternatively, subterminal Galβ1-3GalNAc residues on skeletal muscle glycoproteins might be prevented from interacting with PNA by further modification with terminal sialic acids in normal controls. To address this possibility, we examined the ability of sialidase to expose the cryptic PNA-binding sites on normal skeletal muscle glycoproteins. Digestion of frozen sections from normal controls with C. perfringens sialidase resulted in strong reactivity with PNA on both lectin staining (Figure 4A) and lectin blotting analysis (Figure 4B). This indicates exposure of latent binding sites for PNA in the nontreated DMRV skeletal muscle sections.

To characterize the glycoforms that reacted with PNA, MAA, and WGA in the DMRV skeletal muscle specimens, DMRV skeletal muscle sections were treated with N-glycosidase F. N-Glycosidase F is known to cleave N-linked high mannose and hybrid and complex oligosaccharides. Digestion of frozen skeletal muscle sections from the DMRV patients with N-glycosidase F did not alter the reactivity with PNA (Figure 5), whereas it reduced the reactivity with MAA and WGA (Figure 5). These results indicate that the oligosaccharides that reacted with PNA in the DMRV skeletal muscle specimens were mainly
Figure 2. Lectin histochemical analyses of biopsied skeletal muscle tissues. A: Transverse cryosections of muscle biopsy specimens from normal controls (N1 or N2) and DMRV patients (DMRV-1 and DMRV-5S-2) were stained with rhodamine isothiocyanate-labeled SBA, RCA120, and fluorescein isothiocyanate-labeled MAA and WGA. Increased reactivity for SBA was observed mainly in the connective tissue, the rimmed vacuoles (asterisks), and the cytoplasm of the DMRV atrophic fibers (arrows). RCA120 reactivity was found in the sarcolemmal region, the connective tissue, and the rimmed vacuoles (asterisks) of the DMRV skeletal muscles. B: Transverse cryosections of muscle biopsy specimens from a DMRV patient (DMRV-5S-2) and a MD patient were co-stained with SBA lectin and an antibody against dystrophin. The merged images show that the SBA reactivity was not co-localized with dystrophin, indicating that the SBA-reactive materials were not co-localized with the sarcolemma in the DMRV and MD patients. The most intense SBA reactivity was found in the cytoplasm around rimmed vacuoles of the DMRV patient. SBA reactivity was also found in the connective tissues of both the DMRV and MD patients. Scale bars: 50 μm (A: SBA, MAA, and WGA); 20 μm (A: RCA120, B).
O-linked glycans, whereas those that reacted with MAA and WGA were mainly N-linked glycans.

In DMRV patients, mutation of the GNE gene reduces the enzymatic activity of UDP-GlcNAc 2-epimerase, according to a report by Noguchi and colleagues. Therefore, we measured the sialic acid contents of skeletal muscle specimens from the DMRV patients. Homogenates prepared from the skeletal muscle specimens were subjected to SDS-PAGE before transfer to PVDF membranes. The membranes were cut into eight equal pieces according to decreasing Mr, and then analyzed for sialic acid content by the mild hydrolysis-fluorometric HPLC method. No difference was detected in each membrane slice (Mr 20,000 to >250,000) between the patients and normal controls without glycosidase treatment (data not shown). Then, the skeletal muscle extracts were treated with N-glycosidase F to detect O-linked sialic acid components. A 20% reduction in the total sialic acid content (calculated as sum of the sialic acid contents of membrane slices 1 to 8) was observed in the DMRV muscles on treatment with N-glycosidase F (controls, 4.27 ± 0.46 pmol/μg versus DMRV patients, 3.51 ± 0.26 pmol/μg).

Furthermore, a 20 ~ 40% reduction was observed for

Figure 3. Lectin blot analysis of Triton X solubilized cryosections of muscle biopsy specimens from control subjects including normal ones (N1, N2, and FSHD) and DMRV patients (DMRV-2, DMRV-4, DMRV-5B, and DMRV-5S-1). The samples were electrophoresed and detected with either MAA (A) or PNA (B) lectin.

Figure 4. Effect of sialidase treatment on reactivity of PNA. Normal skeletal muscle glycoproteins react strongly with PNA after digestion with C. perfringens sialidase. A: Lectin staining of transverse cryosections of muscle biopsy specimens from a normal control (N1) and a DMRV patient (DMRV-5S-1) with PNA. Cryosections were treated with (+) or without (−) C. perfringens sialidase. B: A blot of muscle biopsy extracts from a control and a DMRV patient (DMRV-5S-1) was probed with PNA. The extracts were incubated with (+) or without (−) C. perfringens sialidase before electrophoresis and blotting. Scale bars, 50 μm.
each of membrane slice 2 (Mr, 120,000 to 200,000; P = 0.13), slice 3 (Mr, 80,000 to 120,000; P < 0.05), slice 4 (Mr, 60,000 to 80,000; P < 0.05), and slice 6 (Mr, 30,000 to 40,000; P < 0.05) (Figure 6).

Because the reactivity of PNA was significantly increased in the DMRV patients, we tried to identify the sarcolemmal glycoproteins that reacted with PNA. We obtained two fractions for the skeletal muscle extracts according to PNA-binding activity by means of PNA agarose; PNA-binding and PNA-nonbinding fractions. The PNA fraction of the DMRV muscle extracts reacted with a monoclonal antibody, IIH6, that recognizes the carbohydrate epitope of α-DG, but that of a normal control extract did not (Figure 7). By contrast, the PNA-nonbinding fraction of the normal control extract reacted with IIH6 (Figure 7). These data suggest that α-DG contains PNA-reactive sugar chains in the DMRV patients. Furthermore, we examined the expression of glycosylated α-DG in the biop-

Figure 5. Effect of N-glycosidase F treatment on staining with PNA, MAA, and WGA. DMRV skeletal muscle glycoproteins react strongly with PNA but not with MAA or WGA after digestion with N-glycosidase F. Cryosections from a DMRV patient (DMRV-5S-1) were treated with (+) or without (−) N-glycosidase F before lectin staining. Scale bars, 50 μm.

Figure 6. O-Glycan sialylation of skeletal muscle specimens from DMRV patients and controls. The sialic acid contents of skeletal muscle specimens from DMRV patients (n = 4; DMRV-2, DMRV-4, DMRV-5B, and DMRV-5S-1) and controls (n = 3) were determined by the fluorometric HPLC method. Glycoproteins in skeletal muscle homogenates treated with N-glycosidase F were subjected to SDS-PAGE, followed by blotting onto a PVDF membrane, as described in Materials and Methods. The membrane was cut into eight equal pieces according to Mr. Each column represents the means ± SD. *, P < 0.05.

Figure 7. Characterization of PNA-reactive skeletal muscle glycoproteins from DMRV patients by PNA lectin precipitation, followed by Western blotting. Triton X lysis buffer extracts of DMRV-2 (D2), DMRV-5S-1 (D5S-1), and normal control (N2) muscles, each including 100 μg of protein, were subjected to precipitation with PNA agarose. The precipitated proteins (PNA-binding fraction) were blotted with an antibody to α-DG (IIH6). Furthermore, the supernatant (PNA-nonbinding fraction) of the extract with PNA agarose was subjected to precipitation with trichloroacetic acid and then blotted with IIH6.
sied muscle specimens from the DMRV patients with
IIH6. Positive staining was demonstrated in all of the
DMRV patients as well as the normal controls. This sug-
gests that the basic structure of the α-DG sugar chain
recognized by the IIH6 antibody was not altered in the
DMRV patients (data not shown). Immunostaining with
antibodies to β-DG and laminin α2 revealed normal ex-
pression of these substances on the sarcolemmal mem-
brane in the DMRV patients (data not shown).

Discussion

In the current study, we obtained evidence that the hy-
posialylation of O-linked glycoproteins including α-DG
occurs in DMRV skeletal muscles. Enhanced staining
with PNA lectin, which binds core 1 oligosaccharides
(disaccharide Galβ1-3GalNAc), was observed in the sar-
colemma of DMRV skeletal muscles but not in normal
controls or the pathological controls (Figure 1, A and B).
This suggested that sialylated core 1 oligosaccharides
having the structure of Siaα2-3Galβ1-3GalNAc were de-
creased. In contrast, normal reactivity with MAA and
WGA, that mainly bind N-linked sialylated glycans, was
observed in the DMRV muscles (Figures 2A and 3). This
finding suggested that at least sialylation of N-linked gly-
cans was not so severely affected in DMRV. Furthermore,
we have shown that digestion of skeletal muscles from
normal patients with sialidase exposes the latent binding
sites for PNA (Figure 4). Lectin blotting of the DMRV
skeletal muscle extracts with PNA suggested that the
major PNA-reactive bands are those of highly glycosy-
lated glycans (Figure 4). This result suggested that hyper-
glycosylation of core 1 oligosaccharides was decreased.
In contrast, normal reactivity with MAA and
WGA, that mainly react with N-linked sialic acids was per-
formed in this study, and the results showed no significant differences between the
DMRV and control muscles. Because MAA and WGA
mainly react with N-linked sialic acids (Figure 5), we tried
to determine the O-linked sialic acid content in skeletal
muscles from the DMRV patients after N-glycosidase F
treatment. The results revealed that it was reduced to
80% of that in the control muscles. In particular, a 40%
reduction was observed in membrane slice 4 (M, 60,000
to 80,000) and a 32% reduction in slice 6 (M, 30,000 to
40,000) (Figure 6). Our data suggested that the V572L
and G295D/A631V mutations mainly affect the expres-
sion of O-linked sialic acids in muscular glycoproteins.

Despite the increasing number of studies on the
genetics of HIBM/DMRV, little is known about the path-
physiologies of these diseases. In particular, the carbo-
hydrate chain structures of the glycoproteins and their
role have been obscure. It is indispensable to know the
changes in glycosylation of the sarcolemmal glycopro-
teins including the dystrophin-glycoprotein complex
(DGC), which is thought to play an important role as a
transmembrane linker between the intracellular cyto-
skeleton and extracellular components. This will lead to
a better understanding of the roles of carbohydrate
structures in the pathophysiological processes. A candi-
date glycoprotein is α-DG, which has a predominantly
O-linked glycan, including Siaα2-3Galβ1-3GalNAc-Ser/
Thr (α-DG), and rare O-mannosyl glycans consisting of
Siaα2-3Galβ1-4GlcNAcβ1-2Man-Ser/Thr. Fukuyama congenital muscular dystrophy (FCMD)
(OMIM 253800), muscle-eye-brain disease (MEB) (OMIM
253280), and Walker-Warburg syndrome (WWS) (OMIM
236670) are congenital muscular dystrophies with similar
defects in muscular and brain development. Recent stud-
ies have shown that the hypoglycosylation of α-DG,
which was detected as a lack of reactivity with monoclo-
nal antibodies, VIA4–1 and IIH6, recognizing the carbo-
hydrate epitope, is the underlying biochemical defect in
these congenital muscular dystrophies. They have been
called "α-dystroglycanopathies." Recently, Huizing and colleagues reported that HIBM muscles showed
aberrant glycosylation of α-DG similar to in α-dystrogy-
canopathies, whereas several other groups reported that the IIH6 monoclonal antibody showed a normal pattern of expression on the sarcolemmal membrane in DMRV patients.\textsuperscript{16,34} Also, we could not find any significant changes in the immunoreaction of IIH6 with DMRV muscles. Clinically, DMRV usually seems to be moderate when compared with α-dystroglycanopathies, and patients with this disease do not have any apparent brain disorder. This might be because of the fact that the lesion in DMRV is located at the termini of sugar chains of glycoproteins including α-DG and thus the basic structure would be maintained. Furthermore, the residual activity of the GNE gene product would determine the clinical features. Although unique O-linked oligosaccharides on α-DG appear to be critical for interaction with laminin, agrin, perlecan, and neurexin,\textsuperscript{32} treatment of muscle α-DG with sialidase did not affect laminin binding or IIH6 reactivity.\textsuperscript{30} These findings suggested that the indicated laminin binding to muscle α-DG is insensitive to changes in the terminal sialic acid residues. The issues of why O-linked sarcolemmal glycoproteins are predominantly affected and how their hyposialylation results in rimmed vacuoles are predominantly O-glycan formation in sarcolemmal glycoproteins including α-DG. The functional consequence of this finding remains to be determined. Unlike other α-dystroglycanopathies, DMRV/HIBM involve intracellular vacuoles, suggesting that a different pathophysiological mechanism may be involved. Further understanding of the modification of glycoproteins should lead to the development of diagnostic and therapies for DMRV/HIBM.

Acknowledgments

We thank Drs. Kevin Campbell (Howard Hughes Medical Institute, University of Iowa), Stephan Kröger (University of Mainz), Yoshitaka Tanaka (Kyushu University), and A.C.W. Zannettino (University of Adelaide) for the gifts of the antibodies used in this study; and Drs. Takahiko Hara, Yuki Nakayama, Koji Kasahara, Ikuko Wada, and Tamao Endo for the valuable comments.

References


